Revolutionizing Joint Surgery with SYNICEM™ Spacers
In the realm of orthopedic surgery, innovation plays a pivotal role in enhancing patient outcomes. One such advancement is the introduction of the SYNICEM™ spacers by Biocomposites, a renowned international medical devices company. These preformed antibiotic-loaded spacers, designed specifically for hip, knee, and shoulder revisions, exemplify the cutting-edge technology that is transforming surgical practices.
Key Features and Benefits of SYNICEM™ Spacers
The SYNICEM™ antibiotic-loaded spacers are crafted to maintain articular space, limb length, and joint stability during two-stage revision surgeries. They effectively aid in treating infections caused by bacteria sensitive to gentamicin. These spacers are precision-engineered to ensure consistency and structural uniformity, elevating the standard of care in surgical settings. Moreover, they are sterile and ready for use in under a minute, significantly reducing the time demands usually associated with traditional intra-operative customized spacers.
Design and Flexibility
Biocomposites offers a comprehensive range of sizes and styles within the SYNICEM™ spacer collection, providing surgeons with flexibility tailored to specific patient needs. Surgeons can choose between Charnley and Müller hip spacer designs, along with dedicated left and right geometries for knees. This level of customization ensures optimal fit and functionality, ultimately leading to better surgical outcomes.
Proven Track Record
With over 20 years of successful use across more than 70 countries, SYNICEM™ spacers have become a trusted choice among surgeons worldwide. Their reliability in managing challenging infection cases and saving operative time underscores the critical role these devices play in modern orthopedic procedures.
Leadership's Commitment to Quality
Michael Harris, the Chief Executive Officer of Biocomposites, expressed pride in making these vital tools available to Canadian surgeons within months of their U.S. launch. According to Harris, the SYNICEM™ range reflects the company's deep commitment to precision engineering and dependable performance. By enhancing the capabilities of clinicians, Biocomposites aims to improve care for patients with complex medical needs.
About Biocomposites
Biocomposites operates as a global leader in the development of innovative medical devices. Their focus on infection management in bone and soft tissue has positioned them as a market leader with operations spanning Europe, South America, the USA, Canada, China, and India. The company is known for its innovative calcium compounds and bone cements, which are integral in various specialties including musculoskeletal infection, orthopedics, trauma, spine, podiatry, and sports injuries. Biocomposites' products are utilized in over a million procedures annually, reflecting their widespread impact and usefulness in surgical practices globally.
Frequently Asked Questions
What are SYNICEM™ spacers designed for?
SYNICEM™ spacers are designed to maintain joint stability and assist in the treatment of infections during two-stage revision surgeries for hips, knees, and shoulders.
How quickly can SYNICEM™ spacers be used during surgery?
These spacers are sterile and ready to use in under a minute, greatly enhancing operational efficiency.
What makes SYNICEM™ spacers different from traditional options?
Unlike traditional spacers that may require time-consuming molding or customization, SYNICEM™ spacers are preformed, reducing the risk and time associated with their use.
In how many countries are SYNICEM™ spacers available?
SYNICEM™ spacers have been used successfully in over 70 countries, highlighting their global acceptance and reliability.
Who is the Chief Executive Officer of Biocomposites?
The CEO is Michael Harris, who emphasizes quality and consistency in their product offerings.
